SOLV vs. GEHC, PHG, ZBH, SNN, PEN, STVN, IRTC, BLCO, GKOS, and TMDX
Should you be buying Solventum stock or one of its competitors? The main competitors of Solventum include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.
Solventum vs. Its Competitors
GE HealthCare Technologies (NASDAQ:GEHC) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.
In the previous week, GE HealthCare Technologies had 7 more articles in the media than Solventum. MarketBeat recorded 16 mentions for GE HealthCare Technologies and 9 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 0.74 beat Solventum's score of 0.73 indicating that GE HealthCare Technologies is being referred to more favorably in the media.
82.1% of GE HealthCare Technologies shares are held by institutional investors. 0.3% of GE HealthCare Technologies shares are held by company insiders. Comparatively, 0.1% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
GE HealthCare Technologies has a net margin of 11.22% compared to Solventum's net margin of 4.52%. Solventum's return on equity of 29.93% beat GE HealthCare Technologies' return on equity.
GE HealthCare Technologies has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Solventum has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
GE HealthCare Technologies currently has a consensus price target of $85.78, suggesting a potential upside of 15.15%. Solventum has a consensus price target of $84.89, suggesting a potential upside of 17.54%. Given Solventum's higher probable upside, analysts clearly believe Solventum is more favorable than GE HealthCare Technologies.
GE HealthCare Technologies has higher revenue and earnings than Solventum. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.
Summary
GE HealthCare Technologies beats Solventum on 12 of the 17 factors compared between the two stocks.
Get Solventum News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOLV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solventum Competitors List
Related Companies and Tools
This page (NYSE:SOLV) was last updated on 10/8/2025 by MarketBeat.com Staff
